Emerging Areas: Addiction, Neurodegeneration, and More The signals emerging from observational data and early trials are worth discussing, with appropriate scientific humility, because they point to a drug class that may have effects on the brain and reward system that were entirely unanticipated when these drugs were first developed
Following GSH-MEE treatment, the ROS marker CHAC1 decreased in NF-B inhibition cells, and GPX4, the ferroptosis marker, was also rescued (Fig
Hers Hers covers more ground but with caveats: Compounded semaglutide (not FDA-approved) Brand-name GLP-1s: Wegovy, Ozempic, Zepbound, Mounjaro, liraglutide Oral kits : combinations of metformin, bupropion, topiramate, naltrexone (plus sometimes B12) The oral kits
Why They Matter for Fat Loss Growth hormone influences: Lipolysis Fat oxidation Lean mass preservation In research contexts, secretagogues are often explored for their ability to: Improve body composition Support muscle retention during caloric deficit Enhance recovery A GHRH analogue such as CJC-1295 may be studied alongside multi-agonist compounds in body composition protocols to mitigate lean mass reduction during aggressive fat loss phases
